Catharine Paddock PhD

When HIV infects the body, it establishes a key foothold in lymphoid tissue and can persist there, despite potent therapy. But HIV is not dormant in this viral reservoir; the virus continues to replicate, move between tissue compartments and evolve – even when it is undetectable in the blood. HIV continues to replenish its viral reservoir in lymphoid tissue even when it can no longer be detected in the bloodstream. This was the conclusion of a new international study – led by Northwestern University in Chicago, IL, and published in Nature – that provides an important new perspective on how […]

The US Food and Drug Administration have approved a new single tablet as a complete treatment for the treatment of HIV-1 infection in people aged 12 years and over. The new single-tablet HIV drug contains a new form of the powerful HIV inhibitor tenofovir. The new treatment, called Genvoya, from Gilead Sciences, is a fixed-dose combination of elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide. It is intended for patients aged 12 and over, weighing at least 35 kg (77 lbs) and who have never been treated for HIV before, or for infected adults whose HIV is currently suppressed. The drug was […]